Abstract: Objective To compare the treatment effects of propofenofovir combined with fosinopril and entecavir combined with fosinopril on patients with hepatitis B-related IgA nephropathy.Methods Seventy-two patients with hepatitis B-related IgA nephropathy were enrolled in this study, They were divided into two groups based on which treatment regime of antiviral drugs they received. Thirty-five patients in group A were treated with propofol combined with fosinopril, while 37 patients in Group B was treated with entecavir combined with fosinopril. The therapeutic effects were compared at 12 and 24 weeks after treatments. Results In the initial comparison between the two groups, there was no significant difference in gender, average age, 24-hour urine protein quantity, serum albumin, proportion of urine occult blood, systolic blood pressure, diastolic blood pressure, urinary protein creatinine ratio, urea nitrogen, serum creatinine (SCR), LG HBV DNA quantitation. After 12 weeks of treatment, 24-hour urine protein (0.45±0.15 vs. 0.69±0.17, t=-6.208, P<0.01), serum albumin (t=2.799, P<0.01), and the proportion of patients with positive HBV DNA (20% vs. 43.2%, χ² = 4.470, P<0.01) in group B patients were significantly higher than those in group A (P<0.01). Similarly, there was no significant difference in systolic blood pressure, diastolic blood pressure, SCR, urinary occult blood (> 2 +) and urea nitrogen, Lee grade III and above in group A and group B patients at their baselineeline levels. After 24 weeks of treatment, 24-hour urinary protein quantitation (0.13±0.06, vs 0.23±0.08, t=-5.565, P<0.01), serum albumin (t=4.673, P<0.01), systolic blood (t=-5.704, P<0.01), systolic blood pressure (t=-5.704, P<0.01), diastolic blood pressure (t=-2.657, P=0.010), SCR (69.76±22.00, 84.08±18.76,t=-2.986, P<0.01), proportion of patients with positive LG HBV DNA quantitation (8.6% vs 27%, 27%, 27%, 27%, χ²=-4.141, P=0.042), proportion of patients with Lee grade III and above (8.6% vs 29.7%, χ²=3.878, P=0.049) were significant different between the two groups.Conclusion Compared with entecavir combined with fosinopril in the treatment of hepatitis B-related IgA nephropathy, propofenofovir combined with fosinopril has better consequence in reducing urine protein and controlling blood pressure of patients. It is necessary to further extend the follow-up time to confirm the long-term treatment effect.

Key words: Tenofovir alafenamide, Fosinopril, Hepatitis B related IgA nephropathy